Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Loxo Oncology CS (LOXO) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 974,910
  • Shares Outstanding, K 25,550
  • Annual Sales, $ 0 K
  • Annual Income, $ -35,880 K
  • 36-Month Beta 2.89
  • Price/Sales N/A
  • Price/Book 5.34

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.01 +33.69%
on 12/19/16
40.55 -1.06%
on 01/13/17
+13.21 (+49.09%)
since 12/16/16
3-Month
17.14 +134.07%
on 11/03/16
40.55 -1.06%
on 01/13/17
+18.45 (+85.14%)
since 10/18/16
52-Week
16.36 +145.23%
on 02/09/16
40.55 -1.06%
on 01/13/17
+19.45 (+94.10%)
since 01/15/16

Most Recent Stories

More News
Loxo Oncology Announces the Closing of its Follow-On Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced the closing of its...

Loxo Oncology (LOXO) Surges: Stock Moves 25.8% Higher

Loxo Oncology, Inc. (LOXO) moved big last session, as its shares jumped almost 26% on the day.

Loxo Oncology TRK Inhibitor Larotrectinib (LOXO-101) Shows Durable Anti-Tumor Activity Across TRK Fusion Cancers in ESMO Asia Phase 1 Update

- Six of Seven TRK Fusion Patients Achieve Confirmed RECIST Partial Responses and All Remain in Response -

Loxo Oncology to Present Updated LOXO-101 Adult Phase 1 Data at the European Society for Medical Oncology (ESMO) Asia Congress

- Company to Host Investor Conference Call and Webcast on Monday, December 19, 2016 -

Loxo Oncology to Present Preclinical Data for LOXO-292 and LOXO-195 at the 28th EORTC-NCI-AACR Symposium

Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that new preclinical...

Curis Announces Appointment of Lori A. Kunkel, M.D. to Board of Directors

Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced the appointment...

Loxo Oncology Appoints Steve D. Harr, M.D., CFO of Juno Therapeutics, to Board of Directors

Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced the appointment of...

Loxo Oncology to Present at the Stifel 2016 Healthcare Conference

Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that Joshua H. Bilenker,...

Loxo Oncology Announces Third Quarter 2016 Financial Results

- Updated LOXO-101 Phase 1 Clinical Data Accepted for Oral Presentation at ESMO Asia on December 18, 2016 -

Loxo Oncology to Announce Third Quarter 2016 Financial Results

Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, will announce financial results for...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Loxo Oncology, Inc. is a biopharmaceutical company. It develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Loxo Oncology, Inc. is headquartered in Stamford, Connecticut.

See More

Support & Resistance

2nd Resistance Point 42.07
1st Resistance Point 41.10
Last Price 40.12
1st Support Level 38.42
2nd Support Level 36.71

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.